Fasten und Typ-2-Diabetes

Zusammenfassung

Die Prävalenz des Typ-2-Diabetes in Deutschland beträgt annähernd 10 %. Eine kausale Therapie muss darauf abzielen, das viszerale Fett wieder seiner ursprünglichen und natürlichen Bestimmung zuzuführen als Speicher für schlechte Zeiten, der regelmäßig wieder entleert wird. Die Fastentherapie nach Buchinger kann kombiniert mit Bewegung, Entspannung, Ausgleich von Mikronährstoffmangel durch Aktivierung von Reparaturgenen und Autophagie sowohl zu einer oft lange anhaltenden Stoffwechselverbesserung führen als auch die notwendige Motivation zur Lebensstiländerung erzeugen.

Abstract

The prevalence of type 2 diabetes in Germany is nearly 10 %. A causal therapy should aim at using the visceral fat again for its initial and natural purpose as a reservoir for bad times, which is emptied regularly. In combination with physical activity, relaxation, compensation for a micronutrient deficiency by activation of repair genes and autophagy, the fasting therapy according to Buchinger can lead to a long lasting improvement of the metabolism and can create the necessary motivation for changing one’s lifestyle.

Schlüsselwörter

Buchinger-Fasten - Typ-2-Diabetes - Autophagie - Mitohormesis - Lebensstiländerung

Keywords

Fasting therapy according to Buchinger - type 2 diabetes - autophagy - mitohormesis - change of lifestyle

• Literatur

• 1 Wilhelmi de, Buchinger A, Burggrabe H et al Leitlinien zur Fastentherapie; Forsch Komplementärmed. Klass Naturheilkd 2002; 9: 189-198
• 2 Fahrner H. Fasten als Therapie: Buchinger Heilfasten. Stuttgart: Hippokrates; 1985
• 3 Norrelund H, Sreekumaran Na, Lunde Jörgensen JO et al. The proteine-retaining effects of growth hormon during fasting involve inhibition of muscle-proteine break down. Diabetes 2001; 96-104
• 4 Lim EL, Hollingsworth KG, Aribisala BS et al. Reversal of type 2 diabetes: normalisa­tion of beta cell function in association with decreasedpancreas and liver triacylglycerol. Diabetologia 2011; 2506-2514
• 5 Stange R. Fasting therapy improves insulin resistance (HOMA-IR) in patients with the metabolicsyndrome. In: Abstract: North American ResearchConference on Complementary and Integrative Medicine. Edmonton CA: 2006: 34
• 6 Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab 2014; 181-192
• 7 Michalsen A, Li C. Fasting therapy for treating and preventing disease – current state of evidence. Forsch Komplementmed 2013; 444-453
• 8 Michalsen A, Hoffmann B, Moebus S et al. Incorporation of fasting therapy in an inte­grative medicine ward: evaluation of out­come, safety, and effects on lifestyle adherence in a large prospective cohort study. J Altern Complement Med 2005; 601-607
• 9 Huether G, Zhou D, Schmidt S et al. Long-term food restriction down-regulates the density of serotonin transporters in the rat frontal cortex. Biol Psychiatry 1997; 1174-1180
• 10 Hatori M, Vollmers C, Zarrinpar A et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab 2012; 848-860